Uniserve Partners with Logistics Reply to Deliver Transformation to Customers Supply Chains
14.4.2025 10:03:00 CEST | Business Wire | Press Release
Logistics Reply, a company of the Reply Group specialised in digital solutions for the supply chain, has successfully partnered with Uniserve — the UK’s leading independent provider of logistics and global trade management — to implement a cutting-edge warehouse management system (WMS) to meet the growing demand for scalability, efficiency, and real-time visibility across supply chain operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250414470175/en/
With Logistics Reply’s partnership Uniserve faces successfully the challenges of a growing need for scalability and efficiency.
As the leader in logistics innovation for over 40 years, Uniserve worked with Logistics Reply to implement LEA Reply™, a cloud-native, microservices-based platform developed by Logistics Reply.
LEA Reply™ was selected for its scalability and seamless integration with Uniserve's existing infrastructure. The smooth implementation process and ongoing support have significantly enhanced operations, providing real-time inventory visibility across all sites and improving accuracy rates. Since adopting LEA Reply™, Uniserve has increased operational efficiency and laid the foundation for future growth by implementing a scalable platform designed to support business expansion, with plans to integrate advanced technologies—such as AI, inventory drones, yard management, and dock scheduling—in the future.
“We’ve not only improved operations but set the stage for future growth,” said David Barry, Director of Warehouse and Transport at Uniserve. “With LEA Reply™, we can scale operations while maintaining efficiency and accuracy.”
Simon George, Group IT Director at Uniserve, emphasised the importance of the partnership: “What’s great about Logistics Reply is that they’re not just a software vendor; they’re a true strategic partner. We’re excited to roll out more of their solutions, and we know they’ll be there to support us every step of the way.”
This collaboration exemplifies how innovative solutions can optimise logistics, setting new standards for the industry.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major European industrial groups in the telecom and media; industry and services; banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include: consulting, system integration and digital services. www.reply.com
Logistics Reply
Logistics Reply, a Reply Group company, delivers transformative warehouse, store, and supply chain solutions that empower businesses to build efficient, seamlessly connected digital supply chains. By integrating the latest technologies—including artificial intelligence, robotics, wearables, and IoT—Logistics Reply enables seamless interaction between systems, partners, people, and machines. With nearly 30 years of expertise in supply chain technologies and processes, Logistics Reply guides its customers through digital transformation, ensuring rapid time-to-value and lasting operational excellence. www.logistics-reply.com.
Uniserve
Uniserve is the UK’s leading independent logistics and global trade management provider. Founded in 1984, Uniserve has established itself as a pioneer in the logistics industry and employs over 1,500 employees in the UK and Internationally. The business covers every aspect of the supply chain management ecosystem. Seamlessly, combining ocean freight, air freight, road and rail freight services with intelligent warehousing, distribution and supply chain solutions. Where Uniserve sets itself apart is their continuing investment into connected ancillary supply chain services such as customs clearance, consultancy, environmental compliance, finance, bespoke IT systems and education. Uniserve is synonymous with quality, reliability and innovation and a trusted partner to many of the world’s leading businesses.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414470175/en/
Contacts
Press contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom